Chanhong Min

Introduction Monoclonal antibodies (mAbs) have become the dominant class of newly developed drugs and the best-selling drugs worldwide in the pharmaceutical market since the first mAb was approved by the United States Food and Drug Administration (US FDA) in 1986 (Ecker et al., 2015; Lu et al., 2020). To date, most therapeutic mAbs are known to target cancer cells and autoimmune diseases (Stelter et al., 2020).

Abstract Cellular senescence is an established driver of aging, exhibiting context-dependent phenotypes across multiple biological length-scales. Despite its mechanistic importance, profiling senescence within cell populations is challenging. This is in part due to the limitations of current biomarkers to robustly identify senescent cells across biological settings, and the heterogeneous, non-binary phenotypes exhibited by senescent cells.

Abstract The heterogeneous natures of cancer-associated fibroblasts (CAFs) play critical roles in cancer progression, with some promoting tumor growth while others inhibit it. To utilize CAFs as a target for cancer treatment, issues with subtypes of CAFs must be resolved such that specific pro-tumorigenic subtypes can be suppressed or reprogrammed into anti-tumorigenic ones.